93.63
-1.02(-1.08%)
Currency In USD
Address
1 Francis Crick Avenue
Cambridge, CB2 0AA
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 3749 5000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
94300
First IPO Date
May 12, 1993
| Name | Title | Pay | Year Born |
| Pascal Claude Roland Soriot | CEO & Executive Director | 7.07M | 1959 |
| Aradhana Sarin | CFO & Executive Director | 3.43M | 1974 |
| Iskra Reic | Executive Vice President of International | 0 | N/A |
| Ruud Dobber | Executive Vice-President of BioPharmaceuticals Business Unit | 0 | N/A |
| Susan Mary Galbraith | Executive Vice President of Oncology R&D | 0 | 1966 |
| Andrew Barnett | Head of Investor Relations | 0 | N/A |
| David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit | 0 | 1975 |
| Jeffrey Pott | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | 0 | N/A |
| Pam Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | 0 | 1970 |
| Ruth March | Senior VP of Precision Medicine - R&D Oncology | 0 | N/A |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.